Key result
Structural comparisons show SARS-CoV-2 shares TAR-like and Tat-like domains with lentiviruses, revealing therapeutic targets.
Why the study?
SARS-CoV-2 nucleocapsid shares functional and distribution features with lentiviral Tat, suggesting it may transactivate viral and cellular RNAs and serve as a therapeutic target.
Answers are grounded in this paper and cite their sources.
Structural similarities between SARS-CoV-2 and lentiviral Tat proteins suggest shared mechanisms of viral gene expression transactivation, highlighting potential pan-coronaviral therapeutic targets.
Viruses continue to provide vital insights into the field of control of gene expression. Viral transactivators, in concert with other viral and cellular proteins, regulate expression of self, other viruses, and host genes with profound effects on infected cells, underlying inflammation, control of immune responses, and pathogenesis. The multifunctional Tat proteins of lentiviruses (HIV-1, HIV-2, and SIV) transactivate gene expression by recruiting host proteins and binding to trans-acting responsive regions (TARs) in viral and host RNAs. SARS-CoV-2 nucleocapsid participates in early viral transcription, recruits similar cellular proteins, and shares intracellular, surface, and extracellular distribution with Tat. SARS-CoV-2 nucleocapsid interacting with the Replication-Transcription complex might, therefore, transactivate viral and cellular RNAs in transcription and reactivation of self and other viruses, acute and chronic pathogenesis, immune evasion, and viral evolution, constituting a potential pan-coronaviral therapeutic target. Here, we show by using primary and secondary structural comparisons that the leaders of SARS-CoV-2 and other coronaviruses contain TAR-like sequences in stem-loops 2 and 3, the coronaviral nucleocapsid C-terminal domains (N-CTDs) harbor a region of similarity to TAR-binding regions of lentiviral Tat proteins, and the coronaviral nonstructural protein 12 has a cysteine-rich metal binding, dimerization domain similar to that in lentiviral Tat proteins.
No takes yet. Share an insight, caveat, or question.
Patarca et al. (2024) studied Viral gene expression transactivation (HIV-1, SARS-CoV-2). Primary and secondary structural comparisons was evaluated on Structural similarities between coronaviral and lentiviral proteins/RNAs. Primary and secondary structural comparisons revealed that SARS-CoV-2 and other coronaviruses share TAR-like sequences and Tat-like domains with lentiviruses, constituting a potential therapeutic target.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: